Xuefeng He
The First Affiliated Hospital of Soochow University · department of hematology, The First Affiliated Hospital of Soochow University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Xuefeng He as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:33 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07635511 · Acalabrutinib Maleate and Bortezomib for Patients With HLA AntibodiesThe First Affiliated Hospital of Soochow University · not yet recruiting · Hematological Malignancies, Platelet Transfusion Refractoriness (PTR), HLA Antibodies · principal investigator
- Ph4NCT07270835 · Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell LymphomaThe First Affiliated Hospital of Soochow University · recruiting · Hemophagocytic Lymphohistiocytosis, B Cell Lymphoma · principal investigator
- Ph2/Ph3NCT06951971 · Dose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic LymphohistiocytosisThe First Affiliated Hospital of Soochow University · not yet recruiting · Hemophagocytic Lymphohistiocytosis (HLH) · principal investigator
- Ph4NCT06504030 · Modified DEP Regimens for the Treatment of Hemophagocytic LymphohistiocytosisThe First Affiliated Hospital of Soochow University · not yet recruiting · Hemophagocytic Lymphohistiocytoses · principal investigator
- Ph4NCT06066840 · Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal InvolvementThe First Affiliated Hospital of Soochow University · unknown · Safety and Efficacy · principal investigator
- Ph4NCT05039580 · Programmed Cell Death Protein-1 (PD-1) Monoclonal Antibody for EBV-HLH and CAEBV as First-line TherapyThe First Affiliated Hospital of Soochow University · unknown · EBV Infection · principal investigator
- Ph4NCT05021276 · Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHDThe First Affiliated Hospital of Soochow University · unknown · Safety and Efficacy · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:33 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:33 UTC. The ranking covers the 200 most relevant of 605 PubMed records, and a shared surname and initials can bring in a namesake. All 605 on PubMed
- 581 citationsRCR 30.1
- 414 citationsRCR 22.7
- Deciduous autologous tooth stem cells regenerate dental pulp after implantation into injured teeth.Sci Transl Med · 2018381 citationsRCR 18.6
- 356 citationsRCR 18.6
- Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.Lancet Gastroenterol Hepatol · 2022265 citationsRCR 16.1
- 253 citationsRCR 20.3
- CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.Clin Cancer Res · 2021242 citationsRCR 11.7
- Laparoscopic vs Open Distal Gastrectomy for Locally Advanced Gastric Cancer: Five-Year Outcomes From the CLASS-01 Randomized Clinical Trial.JAMA Surg · 2022238 citationsRCR 22.8
- Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309).Cancer Cell · 2023228 citationsRCR 17.3
- Time Outdoors in Reducing Myopia: A School-Based Cluster Randomized Trial with Objective Monitoring of Outdoor Time and Light Intensity.Ophthalmology · 2022208 citationsRCR 27.8